Clinical Trial

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Name: ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors — clinical trial record (NCT07158918)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

Trial Details

NCT Number	NCT07158918
Lead Sponsor	ABL Bio, Inc. Collaborators: Merck Sharp & Dohme LLC
Conditions	Solid Tumors
Enrollment	65 participants
Start Date	2025-08-06
Primary Completion	2027-12-02 (estimated)
Study Completion	2027-12-02 (estimated)
Updated on ClinicalTrials.gov	2025-09-08